Navitoclax, which inhibits BCL-2/BCL-XL/BCL-W, has been extensively tested in lymphoid malignancies and myeloproliferative neoplasms; however, its applicability in AML has proven to be limited due to significant thrombocytopenia, since platelets solely depend on BCL-XL for survival [81,82]. Here, BCL2L1 is linked to myeloproliferative neoplasm.